$BMY Recent Headlines

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2014 at 12:13 PM

$BMY Recent Headlines

GlaxoSmithKline exits cancer drugs
8:36 a.m. Today8:36 a.m. April 22, 2014
- MarketWatch.com

Merck: Hepatitis C drug has 98% cure rate in trial
11:43 a.m. April 10, 2014
- MarketWatch.com

Market rookie Five Prime's shares surge on deal with Bristol-Myers

12:01 p.m. March 17, 2014
- Russ Britt

RadioShack sinks; J.C. Penney gains on S&P outlook hike
5:19 p.m. March 4, 2014
- Sue Chang

Bristol-Myers plans late-stage tests on Yervoy as lung-cancer treatment

5:01 p.m. March 4, 2014
- Russ Britt

Billionaire Stan Druckenmiller's recent moves
12:50 p.m. Feb. 24, 2014
- Insider Monkey

Feds, pharma rivals team up on Alzheimer's

3:32 p.m. Feb. 6, 2014
- Elizabeth O'Brien

Merck hits a new high as analyst sees opening for new cancer drug

12:16 p.m. Jan. 27, 2014
- Russ Britt

U.S. stocks tumble; Dow drops 318 points
6:29 p.m. Jan. 24, 2014
- Anora Mahmudova

Juniper buoyed by Jana stake; Herbalife loss grows
4:50 p.m. Jan. 24, 2014
- Sue Chang

U.S. stock futures trim losses ahead of market open
9:57 a.m. Jan. 24, 2014
- Barbara Kollmeyer

Beam, Honeywell, Procter & Gamble are stocks to watch
6:38 a.m. Jan. 24, 2014
- Sue Chang

AstraZeneca, Bristol-Myers Secure EU OK for Xigduo
3:44 a.m. Jan. 22, 2014
- MarketWatch.com

‘Sloppy’ market turns to consumer, tech earnings
9:01 a.m. Jan. 19, 2014
- Wallace Witkowski

America's best and most generous 401(k)s

3:30 p.m. Jan. 15, 2014
- Anne Tergesen

Merck initiates melanoma filing with FDA
12:45 p.m. Jan. 13, 2014
- Tess Stynes

Statin usefulness questioned, but patent expirations may ease pain

2:02 p.m. Jan. 8, 2014
- Russ Britt

Not all pharmaceuticals are created equal
1:40 p.m. Dec. 26, 2013
- The Trading Deck

FTSE 100 rises, shaking off retail data after Fed taper
1:06 p.m. Dec. 19, 2013
- Sara Sjolin

European stocks rally on Fed taper, rate views
1:00 p.m. Dec. 19, 2013
- Sara Sjolin

Glaxo Exits Cancer Drugs

8:19 a.m. Today8:19 a.m. April 22, 2014
- The Wall Street Journal Interactive Edition

Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff

4:23 p.m. April 21, 2014
- Seeking Alpha

AstraZeneca Shares Rise on Deal Speculation

4:08 p.m. April 21, 2014
- The Wall Street Journal Interactive Edition

Pfizer, AstraZeneca Rise On Report Of Merger Talks

10:13 a.m. April 21, 2014
- Investors Business Daily

3 Stocks Reiterated As A Buy: BMY, XOM, MET

9:59 a.m. April 21, 2014
- TheStreet.com

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside
8:39 a.m. April 21, 2014
- 247WallSt.com

3 Stocks To Capitalize On Advances In Hepatitis C Treatment

8:31 a.m. April 21, 2014
- Seeking Alpha

Big Pharma Q1 Sales Hurt by Exchange Rates

11:34 a.m. April 17, 2014
- Barrons.com

3 Stocks Reiterated As A Buy: BMY, CELG, V

9:59 a.m. April 16, 2014
- TheStreet.com

3 Pharmaceuticals to Profit on Obamacare

6:34 a.m. April 16, 2014
- InvestorPlace.com

New Drug Cocktail Should Boost AbbVie Shares

2:29 p.m. April 15, 2014
- Barrons.com

Bristol-Myers files for HIV-1 combo drug

9:04 a.m. April 14, 2014
- Seeking Alpha

Can Merck, Bristol-Myers, or AbbVie Compete with Gilead’s Cure for Hepatitis C?

8:07 a.m. April 14, 2014
- Wall St. Cheat Sheet

UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo Tablet for Atazanavir Sulfate with Cobicistate

7:08 a.m. April 14, 2014
- benzinga.com

Cramer's Mad Money - 11 Things To Watch In The Week Ahead (4/11/14)

6:28 a.m. April 13, 2014
- Seeking Alpha

3 Stocks Reiterated As A Buy: BMY, LOW, CSCO

3:59 p.m. April 11, 2014
- TheStreet.com

Merck's Hepatitis C Drug May Boost Stock

11:09 a.m. April 11, 2014
- Barrons.com

Market Hustle: Stock Futures Sink as JPMorgan's Profit Shrinks

8:51 a.m. April 11, 2014
- TheStreet.com

Investors: Brace for a Turbulent Second Quarter

1:07 p.m. April 10, 2014
- FOXBusiness

Bristol-Myers Squibb presents Phase III data demonstrating that investigational all-oral daclatasvir and asunaprevir therapy achieved SVR(12) rates of up to 90% among broad range of genotype 1b hepatitis C patients
7:05 a.m. April 10, 2014
- CNW Group

Surveyed U.S. Physicians Expect Strong Uptake of Novel Oral Anticoagulants for the Treatment of VTE
11:30 a.m. April 17, 2014
- PR Newswire - PRF

FluoroPharma Appoints Dr. H. William Strauss, Internationally
Recognized Expert in the Field of Cardiovascular Nuclear Medicine, to
Chair the Scientific Advisory Board
7:27 a.m. April 14, 2014
- Marketwire

Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are Expected to Offer Efficacy Benefits Over Currently Available Treatments
10:00 a.m. April 10, 2014
- PR Newswire - PRF

Earnings Release Schedules, Product Portfolio Expansion, Initiatives and Stock Price Movements - Analyst Notes on Biogen Idec, Bristol-Myers, Regeneron Pharma, Illumina, West Pharma Services
8:00 a.m. April 8, 2014
- PR Newswire - PRF

Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
12:34 p.m. April 7, 2014
- PR Newswire - PRF

Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to
US FDA for the Treatment of Hepatitis C
8:03 a.m. April 7, 2014
- BusinessWire - BZX

Theravance Appoints Kevin Kwok, Head of Talent Acquisition and
Strategy
4:05 p.m. April 1, 2014
- Marketwire

Bristol-Myers Squibb to Announce Results for First Quarter 2014 on
April 29
9:00 a.m. April 1, 2014
- BusinessWire - BZX

Bristol-Myers Squibb Executive Maclean Becomes Precision Health Economics' Chief Operating Officer
10:22 a.m. March 31, 2014
- PR Newswire - PRF

INNATE PHARMA : Start of cohort expansion of Phase I trial with lirilumab and nivolumab in selected solid tumors
1:50 a.m. March 31, 2014
- GlobeNewswire

In A Subanalysis, The Benefits Of Eliquis®
(apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With
Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood
Pressure Control 1
8:16 a.m. March 27, 2014
- BusinessWire - BZX

NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool
4:51 p.m. March 26, 2014
- PR Newswire - PRF

Pharmaceutical Executive to Unveil Brand of the Year Award Recipients at iPharma 2014: CBI's Marketing Innovation Summit
12:11 p.m. March 26, 2014
- PR Newswire - PRF

Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
4:30 p.m. March 25, 2014
- GlobeNewswire

Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
8:00 a.m. March 25, 2014
- PR Newswire - PRF

Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple
Investigational All-oral Combinations across Hepatitis C Genotypes at
The International Liver CongressTM
5:39 a.m. March 24, 2014
- BusinessWire - BZX

FDA Approvals, Financial Highlights, Restated Treatment Indications, and Updates on Product Pipelines - Analyst Notes on Bristol-Myers Squibb, Galena, Teleflex, GW Pharmaceuticals, and CytRx
8:00 a.m. March 21, 2014
- PR Newswire - PRF

Trace One Names Mark Martini as Vice President of North America to
Lead Sales and Customer Development
9:01 a.m. March 20, 2014
- BusinessWire - BZX

Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
8:15 a.m. March 19, 2014
- GlobeNewswire

Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly
8:00 a.m. March 19, 2014
- PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Chinese Congress to Advance Integrative Oncology

Changsha Set to Host a Global Convergence in Oncology For those interested in the blend of age-old wisdom and cutting-edge science, it’s time to tune into what’s happening in Changsha, China. The 2026 Chinese Congress on Holistic Integrative Oncology is about to kick off from November 12 to 15, and it's got quite the lineup of star-studded brainpower in the oncology...

Li-Fire Tackles E-Bike Battery Fires Head-On

E-Bike Enthusiasm Meets Dangerous Fire Risks Imagine this: your sleek new e-bike, your pride and joy, becomes a ticking time bomb. That's the reality facing more folks than we'd like these days, as e-bike battery fires surge across the globe. Amidst the holiday hustle, Li-Fire hits the scene with a lifeline—a free replacement program for their E-bike Lithium Fire Cover....

NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

Burtch Works Joins Databricks: Fueling AI Success

Game-Changer for AI Talent Market First off, let me tell you, in this data-driven world, finding solid AI talent is like hitting the jackpot. Burtch Works teaming up with Databricks? That's like leaping into a goldmine fully prepared. We're talking about forward-deployed engineers and specialized AI talent coming straight to your door. Closing the Impossible Talent Gap...

Ford Foundation's New Funding Boosts Global Flexibility

A Bold New Chapter for Ford Foundation Forget your typical, rigid funding structures; the Ford Foundation is shaking things up. This ain't about just doling out cash and controlling the reigns anymore. Nope, they've pulled the curtain aside to reveal plans for a more agile, empowering approach to sustaining nonprofit partners globally. On the table is a guaranteed 50%...

Historic Ted Williams Baseball Goes Up for Auction

When they say history's for sale, I guess they weren't kidding, were they? Here's a gem from the annals of baseball that might just light up your investment senses—the first Ted Williams-signed baseball from his early days with the Boston Red Sox in 1937 is up for auction. If you're a collector, or even just a baseball romantic, this one's hard to ignore. A Piece of...

Wison's Flex-to-X: Shaping Future of Green Energy

Cracking the Code: Wison's Flex-to-X Debut You'll never catch me tossing into new tech fads blindly, but Wison Engineering's launch of Flex-to-X during ADIPEC 2026 has truly piqued my interest. We're talking about a serious move for green fuels and chemicals, using their chops in modular execution as a springboard into something bigger. From Engineer-to-Order to...

SubSplit Acquires Ideal Consolidated: Legacy Meets Future

Market moves may come and go, but the real power play is knowing when a strategic acquisition is worth its weight in gold. SubSplit Services Group just pulled off one such move by nabbing Ideal Consolidated, Inc., a company that's been a fixture in South Bend, Indiana, since 1956. Yeah, that's a lot of history, folks, and SubSplit's decision to add that to their portfolio...

Budget Airlines' Woes Reveal Travel Insurance Pitfalls

A Turbulent Ride for Travelers Man, it seems like the skies aren't so friendly nowadays, especially if you've got your hard-earned dollars wrapped up in a flight with a budget airline like Spirit or JetBlue. Here's the latest scoop: JetBlue's finances are under the microscope, and if you're planning to fly with them, you better become a travel insurance expert pronto. The...